Truist Securities Reiterates Buy Rating on Arvinas (ARVN), bavdeglutamide Data Matures and Shows Sufficient Evidence of Efficacy and Safety
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $170.00 price target on Arvinas Inc. (NASDAQ: ARVN), following latest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
